Timing of Radiation Pneumonitis in Patients with Stage 3 Non-Small-Cell Lung Cancer Receiving Consolidation Durvalumab after Chemoradiation

Table 1

Patient and clinical characteristics.

Number of patients	N = 31
Age (years)
Median (range)	67 (41, 87)
Gender
Female	14 (45.2)
Male	17 (54.8)
EGFR (for adenocarcinoma or NOS histology)
Negative	14 (45.2)
Positive	7 (22.6)
Unknown	10 (32.2)
ALK
Negative	18 (58.1)
Positive	3 (9.7)
Unknown	10 (32.2)
PDL1
<1%	0
1–49%	23 (74.2)
>50%	8 (25.8)
Stage
Stage 3a	16 (51.6)
Stage 3b	14 (45.2)
Stage 3c	1 (3.2)
Durvalumab
Yes	12 (39)
No	19 (61)
Concurrent chemotherapy
No	5 (16)
Yes	26 (84)
Type of chemotherapy
Cisplatin and etoposide	11 (35.5)
Cisplatin and pemetrexed	7 (22.6)
Carboplatin and paclitaxel	6 (19.4)
Carboplatin and pemetrexed	2 (6.5)
No chemo	5 (16)
Prescription dose
66 Gy in 33	13 (41.9)
60 Gy in 30	18 (58.1)
Completed prescribed dose
Yes	31 (100)
Mean lung dose Gy, mean (SD)	15.8 (1.56)
V5Gy, %, mean (SD)	60.14 (2.73)
V20Gy, %, mean (SD)	29.96 (1.82)

EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; NOS, not otherwise specified; SD, standard deviation.